UPS Stock Forecast: Is the 6.9% Dividend Too Good to Be True?
Parcel delivery giant UPS (NYSE:UPS) has seen its fair share…
Sell
35
JAZZ Quote, Financials, Valuation and Earnings
Last price:
$109.37
Seasonality move
:
44.36%
Day range:
$106.01 - $109.30
52-week range:
$95.49 - $148.06
Dividend yield:
0%
P/E ratio:
14.41x
P/S ratio:
1.70x
P/B ratio:
1.60x
Volume:
958.8K
Avg. volume:
1.3M
1-year change:
3.97%
Market cap:
$6.7B
Revenue:
$4.1B
EPS (TTM):
$7.50
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
JAZZ
Jazz Pharmaceuticals PLC
|
$983.8M | $4.66 | 3.11% | -28.31% | $184.76 |
|
ALKS
Alkermes PLC
|
$304.1M | $0.24 | -14.09% | -21.11% | $39.57 |
|
AMRN
Amarin Corp PLC
|
$50.7M | -$0.40 | -32.65% | -- | $8.00 |
|
AVDL
Avadel Pharmaceuticals PLC
|
$50.6M | -$0.07 | 48.05% | -76.67% | $17.56 |
|
MDT
Medtronic PLC
|
$8.8B | $1.58 | 5.74% | 53.43% | $95.84 |
|
PRGO
Perrigo Co PLC
|
$1.1B | $0.57 | 1.58% | 5557.8% | $34.60 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
JAZZ
Jazz Pharmaceuticals PLC
|
$108.07 | $184.76 | $6.7B | 14.41x | $0.00 | 0% | 1.70x |
|
ALKS
Alkermes PLC
|
$29.35 | $39.57 | $4.8B | 14.04x | $0.00 | 0% | 3.26x |
|
AMRN
Amarin Corp PLC
|
$11.11 | $8.00 | $230.1M | -- | $0.00 | 0% | 1.07x |
|
AVDL
Avadel Pharmaceuticals PLC
|
$9.13 | $17.56 | $883.2M | -- | $0.00 | 0% | 4.52x |
|
MDT
Medtronic PLC
|
$80.68 | $95.84 | $103.4B | 22.29x | $0.70 | 3.47% | 3.10x |
|
PRGO
Perrigo Co PLC
|
$26.56 | $34.60 | $3.7B | -- | $0.29 | 4.21% | 0.84x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
JAZZ
Jazz Pharmaceuticals PLC
|
56.25% | 0.854 | 70.16% | 2.64x |
|
ALKS
Alkermes PLC
|
-- | 1.013 | -- | 2.72x |
|
AMRN
Amarin Corp PLC
|
-- | 0.064 | -- | 2.39x |
|
AVDL
Avadel Pharmaceuticals PLC
|
-- | -2.648 | -- | 2.12x |
|
MDT
Medtronic PLC
|
37.26% | 0.573 | 26.19% | 1.20x |
|
PRGO
Perrigo Co PLC
|
45.39% | 0.039 | 94.29% | 1.05x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
JAZZ
Jazz Pharmaceuticals PLC
|
$793.2M | -$55.9M | 4.93% | 12.12% | -6.25% | $390.9M |
|
ALKS
Alkermes PLC
|
$257.3M | $13.8M | 22.98% | 25.91% | 8.32% | $88.7M |
|
AMRN
Amarin Corp PLC
|
$25.1M | -$16.8M | -16.98% | -16.98% | -39.88% | -$12.5M |
|
AVDL
Avadel Pharmaceuticals PLC
|
$46.9M | -$3M | -35.57% | -35.57% | -4.96% | -$8.2M |
|
MDT
Medtronic PLC
|
$5.8B | $1.8B | 6.12% | 9.51% | 16.08% | $2.1B |
|
PRGO
Perrigo Co PLC
|
$392.3M | $79.4M | -2.12% | -4.01% | 4.53% | -$90M |
Jazz Pharmaceuticals PLC vs. Competitors
-
Which has Higher Returns JAZZ or ALKS?
Alkermes PLC has a net margin of -10.31% compared to Jazz Pharmaceuticals PLC's net margin of 7.33%. Jazz Pharmaceuticals PLC's return on equity of 12.12% beat Alkermes PLC's return on equity of 25.91%.
Company Gross Margin Earnings Per Share Invested Capital JAZZJazz Pharmaceuticals PLC88.35% -$1.52 $9.5B ALKSAlkermes PLC83.95% $0.13 $1.5B -
What do Analysts Say About JAZZ or ALKS?
Jazz Pharmaceuticals PLC has a consensus price target of $184.76, signalling upside risk potential of 70.97%. On the other hand Alkermes PLC has an analysts' consensus of $39.57 which suggests that it could grow by 34.83%. Given that Jazz Pharmaceuticals PLC has higher upside potential than Alkermes PLC, analysts believe Jazz Pharmaceuticals PLC is more attractive than Alkermes PLC.
Company Buy Ratings Hold Ratings Sell Ratings JAZZJazz Pharmaceuticals PLC10 2 0 ALKSAlkermes PLC8 6 0 -
Is JAZZ or ALKS More Risky?
Jazz Pharmaceuticals PLC has a beta of 0.382, which suggesting that the stock is 61.836% less volatile than S&P 500. In comparison Alkermes PLC has a beta of 0.512, suggesting its less volatile than the S&P 500 by 48.82%.
-
Which is a Better Dividend Stock JAZZ or ALKS?
Jazz Pharmaceuticals PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alkermes PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Jazz Pharmaceuticals PLC pays -- of its earnings as a dividend. Alkermes PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios JAZZ or ALKS?
Jazz Pharmaceuticals PLC quarterly revenues are $897.8M, which are larger than Alkermes PLC quarterly revenues of $306.5M. Jazz Pharmaceuticals PLC's net income of -$92.5M is lower than Alkermes PLC's net income of $22.5M. Notably, Jazz Pharmaceuticals PLC's price-to-earnings ratio is 14.41x while Alkermes PLC's PE ratio is 14.04x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Jazz Pharmaceuticals PLC is 1.70x versus 3.26x for Alkermes PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income JAZZJazz Pharmaceuticals PLC1.70x 14.41x $897.8M -$92.5M ALKSAlkermes PLC3.26x 14.04x $306.5M $22.5M
-
Which has Higher Returns JAZZ or AMRN?
Amarin Corp PLC has a net margin of -10.31% compared to Jazz Pharmaceuticals PLC's net margin of -37.36%. Jazz Pharmaceuticals PLC's return on equity of 12.12% beat Amarin Corp PLC's return on equity of -16.98%.
Company Gross Margin Earnings Per Share Invested Capital JAZZJazz Pharmaceuticals PLC88.35% -$1.52 $9.5B AMRNAmarin Corp PLC59.81% -$0.80 $473.7M -
What do Analysts Say About JAZZ or AMRN?
Jazz Pharmaceuticals PLC has a consensus price target of $184.76, signalling upside risk potential of 70.97%. On the other hand Amarin Corp PLC has an analysts' consensus of $8.00 which suggests that it could fall by -27.99%. Given that Jazz Pharmaceuticals PLC has higher upside potential than Amarin Corp PLC, analysts believe Jazz Pharmaceuticals PLC is more attractive than Amarin Corp PLC.
Company Buy Ratings Hold Ratings Sell Ratings JAZZJazz Pharmaceuticals PLC10 2 0 AMRNAmarin Corp PLC0 1 0 -
Is JAZZ or AMRN More Risky?
Jazz Pharmaceuticals PLC has a beta of 0.382, which suggesting that the stock is 61.836% less volatile than S&P 500. In comparison Amarin Corp PLC has a beta of 0.660, suggesting its less volatile than the S&P 500 by 33.97%.
-
Which is a Better Dividend Stock JAZZ or AMRN?
Jazz Pharmaceuticals PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amarin Corp PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Jazz Pharmaceuticals PLC pays -- of its earnings as a dividend. Amarin Corp PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios JAZZ or AMRN?
Jazz Pharmaceuticals PLC quarterly revenues are $897.8M, which are larger than Amarin Corp PLC quarterly revenues of $42M. Jazz Pharmaceuticals PLC's net income of -$92.5M is lower than Amarin Corp PLC's net income of -$15.7M. Notably, Jazz Pharmaceuticals PLC's price-to-earnings ratio is 14.41x while Amarin Corp PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Jazz Pharmaceuticals PLC is 1.70x versus 1.07x for Amarin Corp PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income JAZZJazz Pharmaceuticals PLC1.70x 14.41x $897.8M -$92.5M AMRNAmarin Corp PLC1.07x -- $42M -$15.7M
-
Which has Higher Returns JAZZ or AVDL?
Avadel Pharmaceuticals PLC has a net margin of -10.31% compared to Jazz Pharmaceuticals PLC's net margin of -9.37%. Jazz Pharmaceuticals PLC's return on equity of 12.12% beat Avadel Pharmaceuticals PLC's return on equity of -35.57%.
Company Gross Margin Earnings Per Share Invested Capital JAZZJazz Pharmaceuticals PLC88.35% -$1.52 $9.5B AVDLAvadel Pharmaceuticals PLC89.38% -$0.05 $74.1M -
What do Analysts Say About JAZZ or AVDL?
Jazz Pharmaceuticals PLC has a consensus price target of $184.76, signalling upside risk potential of 70.97%. On the other hand Avadel Pharmaceuticals PLC has an analysts' consensus of $17.56 which suggests that it could grow by 92.28%. Given that Avadel Pharmaceuticals PLC has higher upside potential than Jazz Pharmaceuticals PLC, analysts believe Avadel Pharmaceuticals PLC is more attractive than Jazz Pharmaceuticals PLC.
Company Buy Ratings Hold Ratings Sell Ratings JAZZJazz Pharmaceuticals PLC10 2 0 AVDLAvadel Pharmaceuticals PLC7 0 0 -
Is JAZZ or AVDL More Risky?
Jazz Pharmaceuticals PLC has a beta of 0.382, which suggesting that the stock is 61.836% less volatile than S&P 500. In comparison Avadel Pharmaceuticals PLC has a beta of 1.397, suggesting its more volatile than the S&P 500 by 39.743%.
-
Which is a Better Dividend Stock JAZZ or AVDL?
Jazz Pharmaceuticals PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Avadel Pharmaceuticals PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Jazz Pharmaceuticals PLC pays -- of its earnings as a dividend. Avadel Pharmaceuticals PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios JAZZ or AVDL?
Jazz Pharmaceuticals PLC quarterly revenues are $897.8M, which are larger than Avadel Pharmaceuticals PLC quarterly revenues of $52.5M. Jazz Pharmaceuticals PLC's net income of -$92.5M is lower than Avadel Pharmaceuticals PLC's net income of -$4.9M. Notably, Jazz Pharmaceuticals PLC's price-to-earnings ratio is 14.41x while Avadel Pharmaceuticals PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Jazz Pharmaceuticals PLC is 1.70x versus 4.52x for Avadel Pharmaceuticals PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income JAZZJazz Pharmaceuticals PLC1.70x 14.41x $897.8M -$92.5M AVDLAvadel Pharmaceuticals PLC4.52x -- $52.5M -$4.9M
-
Which has Higher Returns JAZZ or MDT?
Medtronic PLC has a net margin of -10.31% compared to Jazz Pharmaceuticals PLC's net margin of 11.84%. Jazz Pharmaceuticals PLC's return on equity of 12.12% beat Medtronic PLC's return on equity of 9.51%.
Company Gross Margin Earnings Per Share Invested Capital JAZZJazz Pharmaceuticals PLC88.35% -$1.52 $9.5B MDTMedtronic PLC64.75% $0.82 $76.8B -
What do Analysts Say About JAZZ or MDT?
Jazz Pharmaceuticals PLC has a consensus price target of $184.76, signalling upside risk potential of 70.97%. On the other hand Medtronic PLC has an analysts' consensus of $95.84 which suggests that it could grow by 18.79%. Given that Jazz Pharmaceuticals PLC has higher upside potential than Medtronic PLC, analysts believe Jazz Pharmaceuticals PLC is more attractive than Medtronic PLC.
Company Buy Ratings Hold Ratings Sell Ratings JAZZJazz Pharmaceuticals PLC10 2 0 MDTMedtronic PLC12 13 1 -
Is JAZZ or MDT More Risky?
Jazz Pharmaceuticals PLC has a beta of 0.382, which suggesting that the stock is 61.836% less volatile than S&P 500. In comparison Medtronic PLC has a beta of 0.811, suggesting its less volatile than the S&P 500 by 18.855%.
-
Which is a Better Dividend Stock JAZZ or MDT?
Jazz Pharmaceuticals PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Medtronic PLC offers a yield of 3.47% to investors and pays a quarterly dividend of $0.70 per share. Jazz Pharmaceuticals PLC pays -- of its earnings as a dividend. Medtronic PLC pays out 76.98% of its earnings as a dividend. Medtronic PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios JAZZ or MDT?
Jazz Pharmaceuticals PLC quarterly revenues are $897.8M, which are smaller than Medtronic PLC quarterly revenues of $8.9B. Jazz Pharmaceuticals PLC's net income of -$92.5M is lower than Medtronic PLC's net income of $1.1B. Notably, Jazz Pharmaceuticals PLC's price-to-earnings ratio is 14.41x while Medtronic PLC's PE ratio is 22.29x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Jazz Pharmaceuticals PLC is 1.70x versus 3.10x for Medtronic PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income JAZZJazz Pharmaceuticals PLC1.70x 14.41x $897.8M -$92.5M MDTMedtronic PLC3.10x 22.29x $8.9B $1.1B
-
Which has Higher Returns JAZZ or PRGO?
Perrigo Co PLC has a net margin of -10.31% compared to Jazz Pharmaceuticals PLC's net margin of -0.61%. Jazz Pharmaceuticals PLC's return on equity of 12.12% beat Perrigo Co PLC's return on equity of -4.01%.
Company Gross Margin Earnings Per Share Invested Capital JAZZJazz Pharmaceuticals PLC88.35% -$1.52 $9.5B PRGOPerrigo Co PLC37.58% -$0.05 $8B -
What do Analysts Say About JAZZ or PRGO?
Jazz Pharmaceuticals PLC has a consensus price target of $184.76, signalling upside risk potential of 70.97%. On the other hand Perrigo Co PLC has an analysts' consensus of $34.60 which suggests that it could grow by 30.27%. Given that Jazz Pharmaceuticals PLC has higher upside potential than Perrigo Co PLC, analysts believe Jazz Pharmaceuticals PLC is more attractive than Perrigo Co PLC.
Company Buy Ratings Hold Ratings Sell Ratings JAZZJazz Pharmaceuticals PLC10 2 0 PRGOPerrigo Co PLC1 3 0 -
Is JAZZ or PRGO More Risky?
Jazz Pharmaceuticals PLC has a beta of 0.382, which suggesting that the stock is 61.836% less volatile than S&P 500. In comparison Perrigo Co PLC has a beta of 0.448, suggesting its less volatile than the S&P 500 by 55.199%.
-
Which is a Better Dividend Stock JAZZ or PRGO?
Jazz Pharmaceuticals PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perrigo Co PLC offers a yield of 4.21% to investors and pays a quarterly dividend of $0.29 per share. Jazz Pharmaceuticals PLC pays -- of its earnings as a dividend. Perrigo Co PLC pays out -88.77% of its earnings as a dividend.
-
Which has Better Financial Ratios JAZZ or PRGO?
Jazz Pharmaceuticals PLC quarterly revenues are $897.8M, which are smaller than Perrigo Co PLC quarterly revenues of $1B. Jazz Pharmaceuticals PLC's net income of -$92.5M is lower than Perrigo Co PLC's net income of -$6.4M. Notably, Jazz Pharmaceuticals PLC's price-to-earnings ratio is 14.41x while Perrigo Co PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Jazz Pharmaceuticals PLC is 1.70x versus 0.84x for Perrigo Co PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income JAZZJazz Pharmaceuticals PLC1.70x 14.41x $897.8M -$92.5M PRGOPerrigo Co PLC0.84x -- $1B -$6.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will Coinbase Stock Be in 5 Years?
If you’ve been anywhere near the crypto world over the…
How High Will Planet Labs Stock Go in 2025?
Today we dive into Planet Labs (NYSE: PL), the satellite…
Stock Ideas
Buy
65
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 38x
Buy
65
Is NVDA Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 45x
Sell
33
Is AAPL Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 32x
Alerts
Buy
55
SBET alert for May 27
SharpLink Gaming [SBET] is up 454.46% over the past day.
Buy
60
MRUS alert for May 27
Merus NV [MRUS] is down 7.93% over the past day.
Buy
57
RGC alert for May 27
Regencell Bioscience Holdings [RGC] is down 9.77% over the past day.
